GlassScriptPhysician profile
Michelle D Modlinski
NPI 1578951729
$7,830.38
in general payments reported to CMS, 2019-2025
23 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $1,640 · 2023: $1,782 · 2024: $2,103 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,758 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,758.29 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,129.00 | 2021-2025 | |
| Alkermes, INC. | $965.11 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $867.75 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $657.64 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $603.13 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $387.10 | 2021-2025 | Rexulti, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $385.17 | 2021-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $338.44 | 2023-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $294.14 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $292.92 | 2023-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $284.58 | 2021-2022 | |
| Lundbeck LLC | $278.19 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $258.31 | 2024-2025 | Qelbree |
| Neurocrine Biosciences, INC. | $206.78 | 2021-2025 | Ingrezza |
| Noven Therapeutics, LLC | $206.12 | 2024-2025 | Xelstrym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $158.39 | 2023-2025 | Fanapt, Hetlioz |
| Validus Pharmaceuticals LLC | $154.26 | 2023-2025 | Equetro, Raldesy |
| Takeda Pharmaceuticals U.S.A., INC. | $150.62 | 2022-2025 | Trintellix |
| Neos Therapeutics, LP | $62.02 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Tris Pharma INC | $56.68 | 2023-2024 | Dyanavel Xr, Onyda Xr |
| Idorsia Pharmaceuticals US INC | $48.45 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $30.75 | 2021-2022 | |
| Almatica Pharma LLC | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Modlinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.